NCT07477561 Optimizing INtrinsic Capacity for Functional INdependence and to Impede FrailTY in Older Adults: Adaptation of the WHO-ICOPE for Healthy Ageing in Singapore
| NCT ID | NCT07477561 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sengkang General Hospital |
| Condition | Frailty in Older Adults |
| Study Type | INTERVENTIONAL |
| Enrollment | 600 participants |
| Start Date | 2023-07-17 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 600 participants in total. It began in 2023-07-17 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this intervention study is to screen and identify frailty and decline in intrinsic capacity (physical and mental capacities) in community-dwelling older adults in Singapore, and to evaluate whether early identification and targeted interventions can improve health outcomes and support healthy ageing. The main questions it aims to answer are: * Can combined frailty and intrinsic capacity screening with targeted interventions prevent or reduce functional decline in older adults, as measured by changes in life space mobility? * Will at least 80% of screened older adults adhere to recommended care pathways and interventions? * Can this screening and intervention programme demonstrate sustainability through continued community participation and recruitment of new partner organizations beyond the initial implementation phase? The investigators will compare an intervention group (receiving immediate assessment and clinical referrals based on identified needs) to a wait-list control group (receiving the same interventions 12 months later) to see if early intervention leads to better health outcomes and quality of life. Participants will: * Attend 4 study visits over 2 years (at 6-monthly intervals in the first year, with final assessment at end of year 2), each lasting up to 2 hours. * Undergo comprehensive screening assessments including mobility, cognition, mental health, hearing, vision, and nutritional status. * Receive 2 follow-up phone calls at 3-month and 9-month intervals to monitor progress. * If in the intervention group: receive personalized referrals for further care (which may include comprehensive geriatric assessment, primary care reviews, rehabilitation, or dietitian consultations) and guidance on using a mobile health monitoring application. * If in the wait-list control group: receive the same interventions after their 3rd study visit (12 months later).
Eligibility Criteria
Inclusion Criteria: (in Phases 1, 2 and 3): * Any Singaporean or Permanent Resident (PR) aged 60 years and above * Able to provide informed consent (or legally acceptable representative available) Exclusion Criteria (in Phases 1, 2 and 3): * Non-Singaporeans or non-PRs under 60 years of age * Residents of sheltered or nursing homes
Contact & Investigator
Laura Bee Gek Tay
PRINCIPAL INVESTIGATOR
Sengkang General Hospital
Frequently Asked Questions
Who can join the NCT07477561 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, studying Frailty in Older Adults. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07477561 currently recruiting?
Yes, NCT07477561 is actively recruiting participants. Contact the research team at infinity.icope@singhealth.com.sg for enrollment information.
Where is the NCT07477561 trial being conducted?
This trial is being conducted at Singapore, Singapore.
Who is sponsoring the NCT07477561 clinical trial?
NCT07477561 is sponsored by Sengkang General Hospital. The principal investigator is Laura Bee Gek Tay at Sengkang General Hospital. The trial plans to enroll 600 participants.